Syremis Therapeutics Ltd.

Founded in 2025 by co-founders Elisabeth Kogan, Elena Kagan and Menashe Levy and headquartered in Petah Tikva, Israel, Syremis Therapeutics Ltd. specializes in healthcare data analytics solutions. The company raised USD 165 million in a Series A funding round on December 18, 2025, co-led by Dexcel Pharma Technologies Ltd. and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV, QVT Financial and Pictet Alternative Advisors.

The company is also located in Boston, MA. Syremis specializes in delivering innovative data analytics solutions tailored for the healthcare industry. Their core product offerings focus on advanced health information management systems, which facilitate seamless integration of data across various healthcare platforms. These systems enhance clinical decision-making and operational efficiencies by providing real-time insights into patient care, treatment trends, and resource allocation.

The primary end users include hospitals, healthcare providers, and research institutions, which rely on Syremis's solutions to improve patient outcomes and streamline workflows. The company serves a diverse client base across North America and Europe, addressing specific needs within the healthcare sector that have emerged since the launch of their products in recent years. Syremis generates revenue through a subscription-based model, allowing clients to access their suite of healthcare data analytics tools. Transactions typically involve annual contracts with healthcare institutions, which pay fees corresponding to the scale of services utilized.

This structure supports both B2B relationships with large healthcare providers and smaller healthcare facilities seeking to improve their operational capacities. While specific pricing plans for individual products and services are not disclosed, it is understood that Syremis offers tiered solutions, accommodating the varied needs of its clients. The flagship products enable users to derive actionable insights, thereby fostering long-term partnerships within the healthcare ecosystem. In December 2025, Syremis Therapeutics Ltd.

raised USD 165. 00 mn in a Series A funding round, which will be utilized to advance ST‑905 through clinical proof of concept and progress ST‑901 into Phase 1 development for mental health conditions. The company aims to expand its market presence within North America and Europe, focusing on further enhancing its innovative healthcare solutions.